# Verdict: lynch_syndrome.md

## 1. DOSE LEAK
None. Grepped for mg/mg-m2/AUC/Gy/q-schedules/cycle numbers in the sidecar — no matches. The
CAPP2 aspirin dose (75-300 mg/day, in DeVita) is correctly omitted; sidecar only says "aspirin or
placebo."

## 2. UNGROUNDED CLAIMS
None found. Spot-checked every specific/numeric claim against devita.txt:
- "up to one-third of MSI-hi CRCs occur in Lynch syndrome" — verbatim in DeVita (Ch. 40, CRC
  molecular biology section, line ~119033).
- CAPP2 aspirin trial (861 carriers, decreased CRC incidence, trend toward fewer extracolonic
  cancers, no significant GI bleeding/ulcer/anemia increase) — matches DeVita almost word-for-word
  (line ~119978-119986).
- Endometrial cancer risk 40-60% MLH1/MSH2, 16-20% MSH6, ~15% PMS2, younger mean age at diagnosis
  — verbatim match in DeVita endometrial cancer chapter (line ~174238-174250).
- ~15% of Lynch patients at ovarian cancer risk, risk-reducing surgery covers uterus + adnexa —
  matches DeVita ovarian cancer chapter (line ~177889-177895).
- Sexual side effects after risk-reducing hysterectomy/BSO in Lynch carriers (vaginal dryness, pain
  with penetration, decreased arousal) needing dedicated counselling — matches DeVita's sexual
  health chapter almost verbatim (line ~339175-339188), correctly cited as separate from oncologic
  benefit.
- MSI-hi CRC "resist adjuvant fluoropyrimidine... respond better to PD-1 blockade" — directly
  supported by DeVita's own sentence in Ch.40 ("resist adjuvant 5-fluorouracil treatment, and
  respond better to immunotherapy with ... PD-1 blockade than other cancers," line ~119033) AND
  independently corroborated by the Ribic et al. MSI/5-FU adjuvant-benefit data (line ~122630-122650)
  and MSI-hi/checkpoint-inhibitor sensitivity data (line ~119186, ~119549). Sidecar's synthesis is
  fair and not overreaching.
- UTUC as 3rd most common Lynch-associated malignancy, 6% lifetime risk, age <60-65 case-finding
  criteria — verbatim match in DeVita urothelial cancer chapter (line ~152718-152730).
- Draft agent's own "deliberately omitted" claims (no dedicated Lynch treatment section, no
  regimen/RT sequencing found, extension of dMMR/checkpoint rationale to non-CRC Lynch tumors not
  independently grounded) are honestly flagged inline in the sidecar as general-oncology-standard,
  not attributed to DeVita. Correct restraint — no fabrication risk here.
- The one flagged-as-not-DeVita claim (extended vs. segmental colectomy for Lynch-associated CRC) is
  correctly labeled "general oncology standard, not from DeVita's section on this disease" inline —
  consistent with grep results (no DeVita passage on colectomy extent found near Lynch discussion).

## 3. CITATION
Present. Final lines: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
Oncology, 12th ed. NCCN Guidelines: Genetic/Familial High-Risk Assessment - Colorectal." Name only,
no page numbers — compliant.

## 4. VERDICT: CLEAN (ready for R1)

No dose leak, no fabricated regimens/trials/statistics, every DeVita-attributed claim verified
against the source text (5/5 claim clusters cross-checked, including 3 not listed by the draft
agent's own summary — colectomy extent, endometrial/ovarian figures, UTUC figures — all confirmed
independently). Non-DeVita claims are consistently and correctly labeled inline as general
oncology/NCCN standard rather than misattributed to DeVita. Sidecar's own honesty about scope gaps
(no dedicated Lynch treatment section in DeVita, no regimen sequencing, no RT role) is accurate and
appropriately conservative.
